

Please insert the following paragraphs at the top of page 1 of the specification:

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application is a 371 of PCT/DK 03/00426, filed June 23, 2003, which claims priority under 35 U.S.C. § 120 to U.S. provisional application Ser. No. 60/417,399, filed October 09, 2002, and to U.S. provisional application Ser. No. 60/415,214, filed September 30, 2002, and to U.S. provisional application Ser. No. 60/394,120, filed July 03, 2002.

Please delete the paragraph beginning at page 77, line 22, and substitute therefor the following paragraph:

Two vector primers were designed to be used with specific mutation primers:
ADJ013: 5'-GATGGCTGGCAACTAGAAG-3' (SEQ ID NO: 5) (antisense downstream vector primer); and ADJ014: 5'-TGTACGGTGGGAGGTCTAT-3' (SEQ ID NO: 6) (sense upstream vector primer)

Please delete the paragraph beginning at page 77, line 22, and substitute therefor the following paragraph:

To optimize the native N-glycosylation site at position 97 and in order to introduce an additional N-glycosylation site at position 38, the following primers were designed:
S99T:

ADJ093 5'-G TTCAGGTCTGTCACGGTGTAATTGGTCAGCTT-3' (SEQ ID NO: 7)

ADJ094 5'-AAGCTGACCAATTACACCGTGACAGACCTGAAC-3' (SEQ ID NO: 8);

E38N + S40T:

ADJ091 5'-CATGATCTTCCGATCGGTCTCGTTCTTCCAATT-3' (SEQ ID NO: 9)

ADJ092 5'-AATTGGAAGAACGAGACCGATCGGAAGATCATG-3' (SEQ ID NO: 10)

Please delete the paragraph beginning at page 78, line 11, and substitute therefor the following paragraph:

C-terminally modified IFNG variants were generated by one-step PCR using pIGY-54 as template (i.e. including the E38N+S40T+S99T mutations). An ‘upstream’ oligonucleotide containing the start codon (preceded by a BamAI site for cloning and the sequence GCCGCCACC (SEQ ID NO: 13) in order to optimize mRNA translation) and a ‘downstream’ oligonucleotide containing the desired mutation(s) and a XbaI site were used as primers.

Please delete the paragraph beginning at page 78, line 16, and substitute therefor the following paragraph:

In order to optimize protein production, a pcDNA3.1(+)/Hygro(InVitrogen)-derivative plasmid containing an intron from pCI-Neo (Stratagene) was used as expression vector. This vector, termed PF033, was constructed by PCR amplification of the intron from pCI-Neo using 5'-CCGTCAGATCCTAGGCTAGCTTATTGCGGTAGTTTATCAC-3' (SEQ ID NO: 11) and 5'-GAGCTCGGTACCAAGCTTTTAAGAGCTGTAAT-3' (SEQ ID NO: 12) as primers, followed by subcloning of the PCR products into pcDNA3.1(+)/Hygro using NheI and HindIII. The mutated IFNG PCR products were subcloned into PF033 using BamHI and XbaI.

Please delete the SEQUENCE LISTING (numbered as PAGES 1-5) and substitute in its place a paper copy of the “substitute” SEQUENCE LISTING (numbered as pages 1-6), the paper copy of which is attached to Applicants’ Statement under 37 C.F.R. § 1.821 and 1.825.